March 2018

Since the 2008 ASE consensus statement, there have been significant clinical developments, including additional documentation regarding the safety and efficacy of UEA use for improving LVO in several clinical settings. This has been accompanied by the removal and/or reductions of prior contraindications to use and the provision of new clinical data to support use in pediatrics as well as nonapproved indications such as MP imaging and therapeutic thrombolysis. Indeed, the data regarding perfusion imaging is so compelling that European guidelines have recommended UEAs as a method of evaluating patients with stable chest pain.185 A recent meta-analysis